Supreme Court Extends Telemedicine Access to Abortion Pill Mifepristone Through Thursday
Similar Articles
Supreme Court Maintains Telehealth Access to Abortion Pill Mifepristone
Supreme Court Temporarily Blocks Nationwide Ban on Telemedicine Abortion Access
Supreme Court Temporarily Restores Mail-Order Access to Abortion Pill Mifepristone
Appeals Court Blocks Mailing of Abortion Pill Mifepristone, Reinstates In-Person Requirement
Federal Appeals Court Reinstates In-Person Requirement for Mifepristone
The U.S. Supreme Court has extended a freeze on new restrictions for the abortion pill mifepristone, allowing continued access via mail and telemedicine at least through Thursday. The order, issued by Justice Samuel Alito, prevents a lower court ruling from taking effect while the justices consider the case. This maintains the status quo for a method that accounts for one quarter of all abortions in the U.S.
Facts First
- The Supreme Court extended a stay on new mifepristone restrictions through 5 p.m. Thursday.
- Access via mail and telemedicine remains in effect while the court considers a national ban on telemedicine access.
- The 5th Circuit Court of Appeals had ruled to re-institute in-person prescribing rules, which the FDA determined were medically unnecessary.
- Medication abortions accounted for nearly two-thirds of all U.S. abortions in 2023, with a quarter occurring via telemedicine.
- The case stems from a lawsuit by Louisiana, which argues federal rules undermine its state abortion ban.
What Happened
Justice Samuel Alito extended a stay on Monday, preventing restrictions on mifepristone imposed by a federal appeals court from taking effect. The extension allows for the continued mail-order prescribing of mifepristone through 5 p.m. Thursday. The Supreme Court is currently considering whether to allow these restrictions, which would ban telemedicine access, to take effect. The order was granted in response to requests from drugmakers Danco Laboratories and GenBioPro, which manufactures a generic version.
Why this Matters to You
If you or someone you know seeks a medication abortion, the ability to consult with a provider remotely and receive pills by mail may remain an option in the near term. This access is particularly significant in states with abortion bans or limited clinic access. The legal uncertainty, however, could lead to rapid changes in availability. Some providers have stated they would offer alternative protocols if mifepristone access is restricted, which could affect the standard of care you receive.
What's Next
The Supreme Court will decide whether to allow the restrictions from the 5th U.S. Circuit Court of Appeals to take effect. A ruling could come as soon as Thursday. If the court allows the restrictions, access to mifepristone via telemedicine and mail would be suspended nationally, reverting to pre-pandemic rules requiring an in-person doctor visit. The case's outcome could also influence the regulatory power of expert agencies like the Food and Drug Administration (FDA).